Top Market Shifts Transforming the Geographic Atrophy Market Landscape: Key Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Geographic Atrophy Market Through 2025?
The market valuation for geographic atrophy has experienced swift expansion lately, projected to climb from its 2024 figure of $1.86 billion to reach $2.11 billion by 2025, reflecting a compound annual growth rate of 13.7%; this preceding period's upward trend is fundamentally supported by the expanding elderly demographic, the escalating need for therapeutic solutions that demonstrate efficacy, the increasing frequency of geographic atrophy cases, greater public knowledge regarding health matters, and a higher occurrence rate of various retinal afflictions.

What's the Projected Size of the Global Geographic Atrophy Market by 2029?
The market encompassing geographic atrophy is projected to experience swift expansion over the coming years, reaching a valuation of $3.47 billion by 2029, propelled by a compound annual growth rate (CAGR) of 13.2%; this period of growth is anticipated primarily due to escalating emphasis on research, heightened spending in R&D activities, greater prevalence of smartphone utilization, augmented healthcare expenditures, and substantially increased financial backing for clinical studies. Key developments shaping this market landscape will involve progress in gene-based treatments, sophisticated improvements in medical technology, the emergence of novel technical solutions, the broader embrace of virtual healthcare services, and the introduction of groundbreaking, highly efficacious pharmaceutical agents.

View the full report here:
https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Top Growth Drivers in the Geographic Atrophy Industry: What's Accelerating the Market?
Anticipated expansion in the incidence of age-related macular degeneration is set to stimulate the trajectory of the geographic atrophy market moving ahead. AMD, a visual impairment affecting seniors by compromising the retina's core area, results in compromised ability to discern intricate visual information. The primary catalyst behind the widespread occurrence of AMD is the aging demographic, as extended lifespans expose individuals to the cumulative, progressive deterioration of ocular tissues inherent in the aging process, thereby heightening susceptibility to this affliction over time. Therapies for geographic atrophy aid those with AMD by decelerating the advancement of retinal deterioration and safeguarding residual sight. To illustrate, medical news from a US digital publisher, Medical News Today, indicated in January 2024 that worldwide AMD occurrences are projected to climb from 196 million to 288 million within the next two decades. Consequently, the escalating frequency of age-related macular degeneration serves as a significant impetus for the expansion observed in the geographic atrophy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

What Trends Will Shape the Geographic Atrophy Market Through 2029 and Beyond?
Leading firms within the geographic atrophy landscape are prioritizing the creation of sophisticated medical interventions, particularly those employing complement inhibitor technology, as a means to advance care for this condition. Complement inhibitor therapies function by mitigating an excessive immune system reaction associated with specific ailments, thereby safeguarding undamaged cells and slowing the deterioration caused by the disease. To illustrate this progression, Astellas Pharma Inc., a pharmaceutical entity hailing from Japan, revealed in February 2025 that its product, IZERVAY (avacincaptad pegol intravitreal solution), had received sanction from the US regulatory body, the Food and Drug Administration, for addressing geographic atrophy. This official clearance permits the administration of IZERVAY for treating GA secondary to age-related macular degeneration (AMD) without imposing any constraints on the length of the dosing schedule, a development that introduces increased latitude in managing GA and furnishes extended therapeutic possibilities for both the medical community and those affected.

What Are the Main Segments in the Geographic Atrophy Market?
The geographic atrophymarket covered in this report is segmented -

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Complement Inhibitors; Neuroprotective Agents; Other Drugs
2) By Diagnosis: Fundus Autofluorescence (FAF); Optical Coherence Tomography Angiography (OCT-A); Multifocal Electroretinography (mfERG)
3) By Route Of Administration: Intravitreal; Oral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab; Aflibercept; Bevacizumab
2) By Complement Inhibitors: Pegcetacoplan; Lfg316
3) By Neuroprotective Agents: Latanoprost; Brimonidine
4) By Other Drugs: Steroids; Retinoids; Combination Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21984&type=smp

Which Top Companies are Driving Growth in the Geographic Atrophy Market?
Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics

Which Regions Will Dominate the Geographic Atrophy Market Through 2029?
North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21984

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.